Profile data is unavailable for this security.
About the company
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
- Revenue in CHF (TTM)149.02m
- Net income in CHF-652.00k
- Incorporated2002
- Employees156.00
- LocationBasilea Pharmaceutica AG AllschwilHegenheimermattweg 167bALLSCHWIL 4123SwitzerlandCHE
- Phone+41 616061111
- Fax+41 616061112
- Websitehttps://www.basilea.com/
More ▼
Mergers & acquisitions
| Acquired company | BSLN:SWX since announced | Transaction value |
|---|---|---|
| Spexis AG-Preclinical Antibiotics Program | 29.40% | 2.35m |
Data delayed at least 15 minutes, as of Sep 23 2024 16:30 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puretech Health PLC | 397.89k | -70.11m | 386.11m | 90.00 | -- | 1.44 | -- | 970.37 | -0.2258 | -0.2258 | 0.0013 | 0.9904 | 0.0007 | -- | 0.2252 | 3,903.59 | -14.13 | 4.92 | -16.35 | 5.94 | -- | -- | -19,222.22 | 352.67 | -- | -- | 0.0728 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| Valneva SE | 143.09m | -30.75m | 390.23m | 695.00 | -- | 2.12 | 9.46 | 2.73 | -0.2443 | -0.2443 | 1.08 | 1.19 | 0.2988 | 2.25 | 4.70 | 220,443.00 | -6.42 | -15.39 | -9.74 | -25.06 | 38.54 | 35.94 | -21.49 | -34.95 | 2.15 | -2.60 | 0.5577 | -- | -57.46 | 6.34 | 29.21 | -- | 35.18 | -- |
| Oxford BioMedica plc | 101.41m | -178.37m | 425.92m | 714.00 | -- | 4.67 | -- | 4.20 | -1.63 | -1.63 | 0.9273 | 0.7645 | 0.2513 | 3.91 | 3.07 | 125,404.80 | -51.69 | -19.60 | -64.26 | -24.68 | 44.37 | 50.74 | -205.68 | -44.38 | 2.90 | -22.92 | 0.5888 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
| Philogen SpA | 21.95m | -5.85m | 555.02m | 160.00 | -- | 8.90 | -- | 25.29 | -0.1551 | -0.1551 | 0.5747 | 2.25 | 0.1887 | 6.65 | 7.95 | 144,562.50 | -5.03 | -7.32 | -5.56 | -8.36 | 40.04 | 32.04 | -26.64 | -58.66 | 6.84 | -- | 0.1414 | -- | -2.46 | 10.80 | -14.60 | -- | 51.78 | -- |
| Abivax SA | 0.00 | -168.37m | 610.26m | 62.00 | -- | 5.05 | -- | -- | -3.20 | -3.20 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -77.89 | -65.49 | -107.73 | -97.67 | -- | -- | -- | -- | -- | -110.67 | 0.4334 | -- | -- | -- | -111.52 | -- | -19.06 | -- |
| Basilea Pharmaceutica AG Allschwil | 149.02m | -652.00k | 619.64m | 156.00 | -- | 33.97 | 539.75 | 4.16 | -0.2814 | -0.2814 | 11.54 | 1.38 | 0.7118 | 1.22 | 4.40 | 1,013,755.00 | -0.3114 | -1.86 | -0.4156 | -2.99 | 76.57 | 83.45 | -0.4375 | -2.99 | 3.27 | -1.38 | 0.8508 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Kuros Biosciences AG | 52.54m | -8.89m | 757.31m | 80.00 | -- | 12.37 | -- | 14.41 | -0.2295 | -0.2295 | 1.73 | 1.64 | 0.6755 | 1.95 | 7.89 | 656,775.00 | -11.42 | -13.47 | -13.53 | -14.84 | 79.13 | 78.73 | -16.91 | -81.48 | 2.17 | -- | 0.0847 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| Formycon AG | 57.70m | 60.64m | 812.67m | 239.00 | 12.13 | 1.49 | 12.98 | 14.08 | 4.00 | 4.00 | 3.64 | 32.64 | 0.0654 | 34.46 | 1.55 | 255,462.20 | 6.87 | 5.87 | 7.37 | 6.33 | 12.46 | 28.54 | 105.09 | 39.76 | 2.06 | -- | 0.0185 | 0.00 | 82.83 | 12.47 | 110.59 | 60.58 | 81.87 | -- |
Data as of Sep 23 2024. Currency figures normalised to Basilea Pharmaceutica AG Allschwil's reporting currency: Swiss Franc CHF
27.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Black Creek Investment Management, Inc.as of 04 May 2023 | 663.67k | 5.04% |
| CI Investments, Inc.as of 31 Dec 2022 | 642.07k | 4.88% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 450.13k | 3.42% |
| Braginsky Family Office AGas of 13 Sep 2023 | 391.68k | 2.97% |
| Z�rcher Kantonalbank (Investment Management)as of 28 Jun 2024 | 368.26k | 2.80% |
| ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 28 Jun 2024 | 332.69k | 2.53% |
| UBS Asset Management Switzerland AGas of 02 Jul 2024 | 223.67k | 1.70% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Jul 2024 | 193.20k | 1.47% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 190.03k | 1.44% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 175.16k | 1.33% |
More ▼
Data from 13 Sep 2023 - 31 Jul 2024Source: FactSet Research Systems Inc.
